Last reviewed · How we verify
LDL reduction therapy
HMG-CoA reductase inhibitor
HMG-CoA reductase inhibitor Used for Hypercholesterolemia.
At a glance
| Generic name | LDL reduction therapy |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Statins |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
LDL reduction therapy works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver.
Approved indications
- Hypercholesterolemia
Common side effects
- Muscle pain
- Liver enzyme elevation
- Headache
Key clinical trials
- SMART Diets for MASLD (PHASE2)
- Investigation of the Relationship Between Gray and White Matter Volumes, Walking Exercise, and Body Fat Percentage in Adults With a Body Mass Index Above 25 (NA)
- OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome. (NA)
- Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction
- Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial (PHASE4)
- Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population (NA)
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (PHASE4)
- Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |